HTB

2017

Switch study shows F/TAF non-inferior to continuing abacavir/3TC

No transmissions from breastfeeding in Tanzania cohort from mothers with undetectable viral load

Long-acting ART for children is a deferred priority despite achievable dosing

Screening HIV positive pregnant women for TB in South Africa increased detection by 10-fold

Earlier ART reduces infant mortality in South Africa but risk of death and loss to follow up still high

Reducing rates of HIV-related cancer in US from 1996-2012

Dolutegravir use in pregnancy: results from small Belgian cohort

Reassuring French data using raltegravir during pregnancy

16th European AIDS Conference (EACS 2017)

D/C/F/TAF: no impact on bioavailability of when tablet split but TAF reduced when crushed

Dolutegravir linked to less sleep but not cardiovascular or other CNS side effects, or IRIS

Dolutegravir-based dual therapy as switch option in multiple studies

D/C/F/TAF: phase 3 naive results and splitting PI-based FDC tablets

ABX464 nudges viral reservoir but not time to viral rebound

Effects of the anti-inflammatory antibody canakinumab on heart disease and cancer: implications for HIV?

Estimating the total size of the HIV reservoir

Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin

Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results

Updated European guidelines launched at EACS 2017

Future meetings 2017/2018

Featured September/October 2017: Volume 18 Number 9/10

i-Base 2017 appeal: we need your help….

Featured Experts disagree with controversial BMJ support for older HIV drugs in pregnancy

New guides to PrEP

The evidence for U=U (Undetectable = Untransmittable): why negligible risk is zero risk

9th IAS Conference on HIV Science (IAS 2017)

Dual therapy with darunavir/r plus lamivudine as first-line ART

Dual therapy with dolutegravir plus lamivudine as first-line ART

Once-daily raltegravir: 96-week results from the ONCEMRK study

New IPERGAY analysis shows on-demand PrEP dosing works with less frequent sex

On-demand dosing for PrEP is highly effective in French expanded access programme

Psychological impact of PrEP: beyond efficacy and cost-effectiveness

Early ART and testing HIV negative with rapid HIV tests

Report from the IAS HIV Cure & Cancer Forum, 22–23 July 2017, Paris

Generic dolutegravir-based FDCs at US $75 a year for low- and middle-income countries

UK donates well to the Global Fund, but slashed bilateral aid for HIV

Dozens of countries left out of new PEPFAR strategy, threatening the global AIDS response

Gilead uses voucher to speed FDA review of bictegravir

BHIVA challenges BMJ recommendations on ART during pregnancy: tenofovir still strongly recommend

STOPAIDS reviews DFID’s work on HIV and AIDS

UK PrEP guidelines: online for comment

US HIV pain management guidelines (IDSA)

NHS access to PrEP in the UK: country update

Generic PrEP in France and Scotland challenges access across the UK

PrEP use in adolescent gay and bisexual men: US study shows need for easier access and easier PrEP

Enhanced OI prophylaxis reduces mortality when starting ART late

Increased frequency and progression of kidney disease in HIV positive people

HIV and drug adherence: RITA!

September/October 2017: Volume 18 Number 9/10

July/August 2017: Volume 18 Number 7/8

HIV Pipeline Report (2017)

Fit for Purpose: HIV treatment optimisation for adults and children (2017)

i-Base 2017 appeal: we need your help….

9th IAS Conference on HIV Science (IAS 2017)

HIV pipeline drugs: IAS 2017 update

Darunavir/cobicistat/FTC/TAF: 24-week interim results from phase 3 switch study

Phase 3 results with bictegravir FDC: a new integrase inhibitor combined with FTC/TAF

Doravirine/3TC/TDF compared to efavirenz/FTC/TDF as first-line ART

Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results

Reduced-dose darunavir is safe and effective in switch study

MK-8591: further compelling early results for both treatment and prevention

Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study

Preliminary results on dolutegravir use in pregnancy are reassuring

Low dose efavirenz (EFV400) can be used during pregnancy

Stillbirth rate in HIV positive women in UK/Ireland is double that of the general population

Post navigation